|
Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts). |
|
|
Stock and Other Ownership Interests - IHO |
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis |
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis |
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis |
|
|
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer |
Consulting or Advisory Role - ARIAD |
Speakers' Bureau - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer |
Travel, Accommodations, Expenses - ARIAD; Novartis |
|
|
Honoraria - ARIAD; Bristol-Myers Squibb; Incyte; Novartis; Pfizer |
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Incyte; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Gilead Sciences (Inst); Incyte (Inst); Novartis (Inst) |
Expert Testimony - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer |
|
|
|
|
|
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer |
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
Research Funding - ARIAD; Bristol-Myers Squibb; Daiichi Sankyo; Pfizer; Plexxikon |
|
|
Consulting or Advisory Role - Pfizer |
Research Funding - ARIAD; Pfizer |
Travel, Accommodations, Expenses - ARIAD; Pfizer |
|
|
|
Stock and Other Ownership Interests - ARIAD |
|
|
|
|
Stock and Other Ownership Interests - ARIAD |
|
|
|
Stock and Other Ownership Interests - ARIAD |
|
|
|
Stock and Other Ownership Interests - ARIAD |
|
|
Consulting or Advisory Role - Ambit BioSciences; Amphivena Therapeutics; ARIAD; Astellas Pharma; BiolineRx; Bristol-Myers Squibb; Novartis; Pfizer |
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Teva (Inst) |